M&A activity in Biopharma with Datasite | Ep.60
In the first episode of season 3 we discuss the Biopharma industry with Merlin Piscitelli, Chief Revenue Officer of Datasite, SaaS solutions provider for M&A. How will biopharma weather the current economic storm, how is M&A looking and what are the areas being most intensely researched.\n\nGet our free daily newsletter on market movers at www.thearmchairtrader.com\n\nIf there are companies you would like the Armchair Trader to feature in future episodes reach us on www.thearmchairtrader.com\n\n0.37 A summary of recent activity\n2.10 Do you anticipate more major acquisitions?\n3.27 Are recent valuations unrealistically high?\n6.55 Is there an innovation deficit and if so, does that impact deal activity?\n9.43 Will we see downward pressure from private equity from on high prices?\n13.06 How will the biopharma weather the economic storm?\n15.55 M&A activity in biopharma versus other sectors\n17.28 Will diversification lead to more cross-sector transactions?\n18.51 Activist investors\n20.15 Does a UK recession impact global biopharma M&A?\n21.51 Approval rates and their effect on M&A\n24.27 What's the biggest research focus at the moment?